No Data
Keqian Biology: Wuhan Keqian Biology Co., Ltd. 2024 Annual Performance Report Announcement
Wuhan Keqian Biology Co., Ltd. 2024 Annual Results Express Announcement
Wuhan Keqian Biology Co.,Ltd (688526.SH): Net income of 0.375 billion yuan in 2024, a decrease of 5.27% year-on-year.
Gelonghui reported on February 26 that Wuhan Keqian Biology Co., Ltd. (688526.SH) announced the annual performance report for 2024, with revenue reaching 0.948 billion yuan, a decrease of 10.92% compared to the previous year; and a net income attributable to the parent company's owners of 0.375 billion yuan, a decrease of 5.27% compared to last year. During the reporting period, as market competition intensified, competition for some highly homogeneous products became fierce, leading to a decline in the company's revenue and net income. In response to the increasingly competitive market environment, the company continues to increase its R&D efforts, accelerate the development of new products, and constantly enhance its market competitiveness.
China Galaxy Securities 2025 Annual Strategy for the Agriculture, Forestry, Animal Husbandry, and Fishery Industry: Focusing on the Breeding Industry Chain, Looking Forward to Efficiency and Growth.
To further boost the growth Sector, investment opportunities in Agriculture in 2025 can still revolve around the breeding Industry Chain.
Wuhan Keqian Biology Co., Ltd (688526.SH): Plans to sign a cooperative research and development agreement with Huazhong Agricultural University.
On December 9th, Gelonghui reported that wuhan keqian biology co.,ltd (688526.SH) announced that in order to enhance the company's market competitiveness and accelerate the development in the biological product industry, thereby better enhancing the company's brand influence and core competitiveness, according to the "Articles of Association," "Cooperative Research and Development Management System," and other regulations, after competitive negotiations with Huazhong Agricultural University, the company has obtained a trivalent inactivated vaccine for chicken infectious rhinitis (Type A + Type B + Type C, recombinant protein), chicken Mycoplasma synoviae, chicken Mycoplasma gallisepticum (HB03 strain + HB15 strain), recombinant Newcastle disease virus, infectious bronchitis virus, and bird flu virus (H9 subtype), and infectious law.
wuhan keqian biology co.,ltd (688526.SH): has repurchased 0.4296% of the shares accumulated.
On November 4, Gelonhui announced that as of October 31, 2024, Wuxi Keqian Biology Co., Ltd. (688526.SH) has repurchased a total of 2,002,347 shares of the company through the Shanghai Stock Exchange trading system in a centralized competitive bidding trading manner, accounting for 0.4296% of the company's total share capital of 466,128,056 shares. The highest repurchase price was 18.90 yuan/share, the lowest price was 13.29 yuan/share, and the total amount paid was RMB 32,945,273.72 (excluding stamp duty, trading commissions, and other trading expenses).
